# Luminopia

> Luminopia is a commercial-stage digital therapeutics company that turns a child's favorite TV shows into FDA-cleared medicine for amblyopia (lazy eye). Children wear a VR headset for one hour a day, six days a week, and watch curated, real-time-modified episodes that retrain the brain to use both eyes together. Founded by Harvard dropouts and incubated at Boston Children's Hospital, Luminopia One became the first FDA-approved digital therapeutic for a neuro-visual disorder.

- **Founded:** 2015
- **Headquarters:** Cambridge, Massachusetts, United States
- **Founders:** Scott Xiao (Co-Founder & CEO), Dean Travers (Co-Founder)
- **Team size:** ~23 employees
- **Products:** Luminopia One, Curated Content Library, Adherence & Prescription Portal
- **Notable:** First FDA-approved digital therapeutic for amblyopia and for any neuro-visual disorder (De Novo, October 2021)., Phase 3 trial: treated eye visual acuity improved ~1.8 lines on a logMAR chart at 12 weeks vs ~0.8 lines for control., FDA clearance expanded in 2025 from ages 4-7 to ages 4 to under 13.

## Products & services

- **Luminopia One** — FDA-cleared, prescription-only binocular digital therapeutic for amblyopia. Children watch therapeutically-modified TV shows and movies in a VR headset for one hour a day, six days a week. Dual-acting algorithms alter the video in real time to encourage use of the weaker eye and combine input from both eyes.
- **Curated Content Library** — A library of popular kids' programming licensed from partners including Nickelodeon, Sesame Workshop, PBS Kids, The Pokemon Company, and Crunchyroll, modified for therapeutic use.
- **Adherence & Prescription Portal** — A platform for eye care providers to prescribe treatment and monitor patient adherence remotely.

## Achievements

- First FDA-approved digital therapeutic for amblyopia and for any neuro-visual disorder (De Novo, October 2021).
- Phase 3 trial: treated eye visual acuity improved ~1.8 lines on a logMAR chart at 12 weeks vs ~0.8 lines for control.
- FDA clearance expanded in 2025 from ages 4-7 to ages 4 to under 13.
- Raised an oversubscribed $16M Series A in 2023 to fund commercial rollout.
- Backed by Sony Innovation Fund and Sesame Workshop.

## Latest updates

- **2025-10** — Collaborated with Crunchyroll to add anime to the curated content library for pediatric patients.
- **2025-08** — Partnered with The Pokemon Company to expand the content library.
- **2025-04** — FDA granted expanded clearance covering patients aged 8 to 12, extending the label to ages 4 to under 13.
- **2023-06** — Closed an oversubscribed $16M Series A led by U.S. Venture Partners to fund commercial rollout.
- **2021-10** — Received FDA De Novo authorization for Luminopia One.

## Links

- Website: https://luminopia.com
- LinkedIn: https://www.linkedin.com/company/luminopia
- Twitter/X: https://twitter.com/luminopia
- YouTube: https://www.youtube.com/channel/UCNR65lYiDYUchhCCZTgyxiw
- Facebook: https://www.facebook.com/luminopia/

---

Profile page: https://yespress.io/luminopia
Published by YesPress — https://yespress.io
Last updated: 2026-06-07